Search

Displaying results 2901 - 2910 of 7059 in total
  1. Drug

    Fulimetibant

    go.drugbank.com/drugs/DB21599
    Experimental

    Fulimetibant has a monoisotopic molecular weight of 487.15 Da. … Fulimetibant is a small molecule drug. The usage of the INN stem '-tibant' in the name indicates that Fulimetibant is a bradykinin receptor antagonist.

  2. Drug

    Adrixetinib

    go.drugbank.com/drugs/DB21620
    Investigational

    Adrixetinib has a monoisotopic molecular weight of 531.17 Da. … Adrixetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Adrixetinib is a tyrosine kinase inhibitor.

  3. Drug

    Friluglanstat

    go.drugbank.com/drugs/DB21652
    Experimental

    Friluglanstat has a monoisotopic molecular weight of 516.12 Da. … Friluglanstat is a small molecule drug. The usage of the INN stem '-glanstat' in the name indicates that Friluglanstat is a prostaglandin synthase inhibitor.

  4. Drug

    Canlitinib

    go.drugbank.com/drugs/DB21656
    Experimental

    Canlitinib has a monoisotopic molecular weight of 619.21 Da. … Canlitinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Canlitinib is a tyrosine kinase inhibitor.

  5. Drug

    Labuxtinib

    go.drugbank.com/drugs/DB21658
    Experimental

    Labuxtinib has a monoisotopic molecular weight of 377.13 Da. … Labuxtinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Labuxtinib is a tyrosine kinase inhibitor.

  6. Drug

    Talorasib

    go.drugbank.com/drugs/DB21686
    Experimental

    Talorasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Talorasib is a Ras protein inhibitor. Talorasib has a monoisotopic molecular weight of 604.24 Da.

  7. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905] … [L33340] A companion diagnostic device - the VENTANA MMR RxDx Panel - was also approved alongside this indication to select appropriate patients for treatment.

  8. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.

  9. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin A immune FAB2 (equine), BOTULINUM NEUROTOXIN A IMMUNE FAB2, EQUINE
  10. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. … From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions.